Foundayo vs Wegovy Pill: Which Oral GLP-1 for Weight Loss?
Prices and FDA status checked in November 2026 and subject to change.

Foundayo™ and the Wegovy® pill are the two FDA-approved daily GLP-1 pills for weight loss, and the choice comes down to a trade between weight loss and convenience. In its 64-week trial, adults on the Wegovy pill's 25 mg dose lost an average of 13.6% of their body weight, compared with 2.4% on placebo. In Foundayo's 72-week trial, adults on the top 17.2 mg dose lost 11.1%, compared with 2.1%. These were separate trials, and no trial has compared the two pills for weight loss. Foundayo can be taken at any time, with or without food. The Wegovy pill must be taken on an empty stomach, followed by a 30-minute wait. As of November 2026, both cost $149 to $299 a month through the makers' self-pay programs.
If you'd rather take a weekly shot and pay cash, MaxLife offers compounded semaglutide at $89/mo flat and compounded tirzepatide at $120/mo flat, prescribed only if a licensed provider decides it's right for you. Compounded medicines are not FDA-approved, they are injections rather than pills, and they are not Wegovy or Foundayo.
Foundayo vs Wegovy Pill at a Glance
| Foundayo | Wegovy pill | |
|---|---|---|
| Medicine | Orforglipron | Semaglutide |
| Maker | Eli Lilly | Novo Nordisk |
| Type of molecule | Small molecule (not a peptide) | Peptide, with an absorption enhancer (SNAC) |
| FDA approval | April 1, 2026 | December 22, 2025 |
| Approved uses (adults) | Weight loss and keeping it off | Weight loss and keeping it off; lowering the risk of heart attack, stroke and heart-related death in people with heart disease |
| How you take it | Once a day, any time, with or without food | Once a day in the morning on an empty stomach, with up to 4 ounces of water, then a 30-minute wait |
| Top dose | 17.2 mg | 25 mg |
| Average weight loss at the top dose | 11.1% at 72 weeks (placebo 2.1%) | 13.6% at 64 weeks (placebo 2.4%) |
| Lost 20% or more | 18.4% of people | 27.9% of people |
| Stopped because of side effects | 6% to 10% (placebo 3%) | 6.9% (placebo 5.9%) |
| Storage | Room temperature | Room temperature, in the original bottle |
| Self-pay price, November 2026 | $149 to $299 for 30 tablets ($349 for the top two doses if you refill late) | $149 to $299 for 30 tablets |
| Medicare GLP-1 Bridge | $50 a fill if you qualify | $50 a fill if you qualify |
Sources: the Foundayo label and the Wegovy label on DailyMed, LillyDirect, NovoCare and Medicare.gov, checked November 2026. Weight results come from separate trials.
Is Foundayo a Semaglutide? What Makes the Two Pills Different
No. Foundayo contains orforglipron, a newer medicine from Eli Lilly. The Wegovy pill contains semaglutide, the medicine in Novo Nordisk's Wegovy and Ozempic® injections. Both switch on the GLP-1 receptor, which helps lower appetite and slows how fast the stomach empties, but they are built differently:
- Different molecules. Orforglipron is a small, non-peptide molecule that the gut absorbs well: in label testing, about 77% of a dose reached the bloodstream. Semaglutide is a peptide that the stomach breaks down, so the Wegovy pill adds an absorption helper called SNAC, and even then only about 1% to 2% of each dose is absorbed. That is why the pill's 25 mg daily dose is so much larger than the 2.4 mg weekly injection, and why it comes with strict food and water rules.
- Different time in the body. Foundayo's half-life is about 29 to 49 hours; semaglutide's is about a week.
- Different makers. Lilly sells Foundayo through LillyDirect, and Novo Nordisk sells the Wegovy pill through NovoCare. Each company ran its own trials.
Neither pill is a tirzepatide, the medicine in Zepbound® and Mounjaro®. As of November 2026, no tirzepatide pill exists.
Is Foundayo or the Wegovy Pill Better for Weight Loss?
On average, the Wegovy pill produced more weight loss in its trial, but because the two pills were tested in separate trials, the gap is an estimate, not a proven difference. Both trials enrolled adults with obesity, or overweight plus a weight-related health problem, without diabetes. Both labels count everyone who was randomized, including people who stopped taking the pill:
| Result | Foundayo 17.2 mg (72 weeks) | Wegovy pill 25 mg (64 weeks) |
|---|---|---|
| Average weight loss | 11.1% (placebo 2.1%) | 13.6% (placebo 2.4%) |
| Lost at least 5% | 71.5% (placebo 26.8%) | 76.3% (placebo 31.3%) |
| Lost at least 10% | 54.5% (placebo 13.0%) | 59.8% (placebo 14.4%) |
| Lost at least 15% | 35.9% (placebo 6.0%) | 47.0% (placebo 5.5%) |
| Lost at least 20% | 18.4% (placebo 2.9%) | 27.9% (placebo 3.1%) |
Sources: Table 6 of the Foundayo label (the ATTAIN-1 trial, 3,127 adults) and Table 11 of the Wegovy label (the OASIS 4 trial, 307 adults). Both trials were published in The New England Journal of Medicine (ATTAIN-1, OASIS 4).
In pounds, that's about 25 pounds on Foundayo's top dose, according to Lilly, and about 32 pounds on the Wegovy pill, by our math from the trial's average starting weight of 235 pounds. Foundayo's lower doses produced 7.4% (5.5 mg) and 8.3% (9 mg).
You may also see higher numbers: 12.4% for Foundayo and 16.6% for the Wegovy pill. Those are the makers' estimates of what would have happened if everyone had stayed on treatment. Compare 11.1% with 13.6%, or 12.4% with 16.6%, but not one of each. Some articles mix them.
The trials also differed. Foundayo's ran 8 weeks longer and was 10 times larger, and the two used different dose schedules. So is Foundayo better than Wegovy for weight loss? Based on what's published, not on average. Still, more than half of the people on Foundayo's top dose lost at least 10% of their weight. These results belong to Foundayo and the Wegovy pill in their own trials; they have not been shown for compounded semaglutide or compounded tirzepatide.
Has Foundayo Been Tested Against Oral Semaglutide?
Yes, once, but not against the Wegovy pill and not for weight loss. The ACHIEVE-3 trial, published in The Lancet in 2026, compared orforglipron with oral semaglutide for 52 weeks in 1,698 adults with type 2 diabetes who were taking metformin. It was funded by Lilly, and participants knew which drug they took.
- Blood sugar: both orforglipron doses lowered A1C more than both semaglutide doses, which was the trial's main goal.
- Weight: at the top doses, people lost 9.2% of their body weight on orforglipron and 5.3% on oral semaglutide, according to Lilly's report, which estimates results as if everyone had stayed on treatment.
- Side effects: more people stopped orforglipron because of side effects (9% and 10%) than oral semaglutide (4% and 5%), and stomach and bowel side effects were more common (58% to 59% versus 37% to 45%).
Three limits matter. The semaglutide tablets were 7 mg and 14 mg, the diabetes doses sold as Rybelsus®, not the Wegovy pill's 25 mg. Everyone had type 2 diabetes. And Foundayo is not FDA-approved to treat type 2 diabetes in the U.S. as of November 2026. So ACHIEVE-3 shows that orforglipron beat lower-dose oral semaglutide on blood sugar and weight in people with diabetes. It doesn't settle Foundayo vs the Wegovy pill for weight loss.
How Do You Take Foundayo vs the Wegovy Pill?
The daily routine is the biggest practical difference.
Foundayo: one tablet a day, swallowed whole, with or without food. The label lists no water limit or waiting time, and Lilly says it can be taken at any time of day. Don't break, crush or chew it, and never take more than one tablet a day.
Wegovy pill: one tablet each morning on an empty stomach, with up to 4 ounces of plain water and no other drink. Swallow it whole. Then wait at least 30 minutes before you eat, drink anything else or take other pills. In the label's studies, less water and a longer wait before eating meant more of the medicine was absorbed.
Both start low and step up to lower the risk of stomach side effects:
| Step | Foundayo | Wegovy pill |
|---|---|---|
| Starting dose | 0.8 mg | 1.5 mg |
| Second step | 2.5 mg | 4 mg |
| Third step | 5.5 mg | 9 mg |
| Higher doses | 9 mg, 14.5 mg or 17.2 mg if needed and tolerated | 25 mg (maintenance) |
Each Foundayo step lasts at least 30 days. The Wegovy pill moves up every 30 days and reaches 25 mg on day 91. If the 25 mg pill isn't tolerated, the Wegovy label suggests switching to the 1.7 mg weekly injection.
Missed doses: take a missed Foundayo dose as soon as you can, but never two in a day; after 7 or more missed days in a row, the dose has to be built up again. Skip a missed Wegovy pill and take the next one the following day.
Storage: both are kept at room temperature, 68°F to 77°F. Keep Wegovy pills in their original bottle to protect them from moisture. Your provider sets your dose and schedule.
Foundayo vs Wegovy Pill Side Effects
Both mainly cause stomach and bowel side effects, most often while the dose is going up. The labels report them differently, so an exact side-by-side isn't possible. Foundayo's label has its own table. The Wegovy label says only that the 25 mg pill's common side effects were "similar" in type and frequency to those of the Wegovy injection (where nausea affected 44% of people, versus 16% on placebo).
| Measure | Foundayo 5.5 to 17.2 mg | Wegovy pill 25 mg |
|---|---|---|
| Any stomach or bowel side effect | 60% to 69% (placebo 37%) | 74.0% (placebo 42.2%) |
| Severe stomach or bowel side effects | About 3% (placebo 1%) | 2% (placebo 0%) |
| Stopped because of side effects | 6% to 10% (placebo 3%) | 6.9% (placebo 5.9%) |
| Nausea | 26% to 35% (placebo 10%) | No separate figure in the label |
Sources: the Foundayo label (two trials pooled); for the Wegovy pill, the label and the OASIS 4 paper, which gives the first row. Different trials and definitions, so treat this as a rough guide.
Does Foundayo cause fewer side effects than the Wegovy pill? Not clearly. In ACHIEVE-3, at diabetes doses, stomach side effects and stopping were more common with orforglipron. Other points from the labels:
- Shared warnings. Both carry a boxed warning about thyroid C-cell tumors, and neither should be used with a personal or family history of medullary thyroid carcinoma or MEN 2. Both list pancreatitis, gallbladder problems, kidney problems from dehydration, low blood sugar when used with insulin or a sulfonylurea, eye problems in people with type 2 diabetes, and a risk of food entering the lungs during anesthesia. Tell your care team before any procedure.
- Eyes. On November 9, 2026, the FDA said it is requiring the labels of all GLP-1 medicines, including Foundayo and Wegovy, to add a possible increased risk of NAION, a rare condition that can cause sudden, painless vision loss in one eye. As of November 2026, neither label on DailyMed had been updated. Get care right away for any sudden vision change.
- Birth control pills (Foundayo). The label advises switching to a non-oral method, or adding a barrier method, for 30 days after you start and for 30 days after each dose increase. The Wegovy label has no such advice.
- Other medicines. The Wegovy pill raised levothyroxine (thyroid medicine) levels by 33% in a study, and its 30-minute rule applies to other morning pills. Foundayo is broken down by the liver enzyme CYP3A4, so some medicines change its levels; with strong CYP3A4 blockers, its top dose is 9 mg.
- Breastfeeding. Neither label recommends it during treatment. The Wegovy label points to SNAC, which passes into breast milk.
- Liver and diabetes. Foundayo is not recommended with severe liver disease. The Wegovy label warns that some people with type 2 diabetes may get lower-than-needed semaglutide levels from the pill.
Talk to your provider about any side effect that worries you, and share a full list of your medicines.
Foundayo vs Wegovy Pill Cost
Without insurance, the two pills cost about the same. Here are the makers' self-pay prices for 30 tablets, as of November 2026:
| Step | Foundayo (LillyDirect) | Wegovy pill (NovoCare) |
|---|---|---|
| Starting dose | $149 (0.8 mg) | $149 (1.5 mg) |
| Second step | $199 (2.5 mg)* | $199 (4 mg) |
| Third step | $299 (5.5 mg)* | $299 (9 mg) |
| Higher doses | $299 (9, 14.5 or 17.2 mg)† | $299 (25 mg) |
| List price | $649 | $1,349.02 |
* Reduced prices through December 31, 2026: $149 (2.5 mg) and $199 (5.5 mg). † $349 for 14.5 or 17.2 mg if you don't refill within 45 days.
Sources: LillyDirect Foundayo and its terms, NovoCare, and list prices from TrumpRx.gov, which labels them wholesale acquisition cost. Checked November 2026.
At regular prices, the two price ladders match: $149, then $199, then $299 a month. A first year following each label's steps comes to about $3,338 for either pill ($149 + $199 + 10 × $299), by our math. Foundayo's reduced prices bring that down to about $3,188 while they last, and its top two doses rise to $349 if you refill late. Novo Nordisk will cut the Wegovy pill's list price to $675 on January 1, 2027, but it says self-pay prices won't change.
With insurance: if your commercial plan covers the pill, the makers' savings cards can bring it to as little as $25 a month. Both cap savings at $100 a month, and the Foundayo card ends December 31, 2026. Many plans exclude weight-loss drugs: in 2026, 18% of firms with 200 or more workers covered GLP-1s for weight loss (KFF). Our guide to weight loss drugs covered by insurance explains prior authorization.
With Medicare: both pills are covered for $50 a fill through the Medicare GLP-1 Bridge, which runs through December 31, 2027, for Part D members who meet its BMI and health rules. People with type 2 diabetes, moderate to severe sleep apnea or fatty liver disease are not eligible for the Bridge, though their Part D plan may cover a GLP-1.
For every GLP-1's price in one place, see our GLP-1 cost guide, or estimate your own monthly cost with the GLP-1 cost calculator.
Can You Switch From Wegovy to Foundayo?
Yes, with your provider, but there's no official dose conversion. The best data come from the Lilly-funded ATTAIN-MAINTAIN trial. Adults whose weight loss had leveled off on Wegovy injections switched to orforglipron or a placebo. After a year, the orforglipron group had kept 79.3% of the weight they had lost, compared with 37.6% on placebo. Lilly reported that they regained about 0.9 kg (2 pounds) on average.
Two limits: the trial had no group that stayed on Wegovy, and nobody switched from the Wegovy pill. A few rules apply either way:
- Never take them together. Both labels say not to combine them with another GLP-1 medicine.
- Your provider picks the starting dose. Neither label gives a conversion between the two drugs.
- Switching within Wegovy is different. The Wegovy label does give rules for moving between its own pill and injection; our Wegovy pill vs injection guide covers them.
Foundayo or the Wegovy Pill: Which Might Suit You?
Your provider will weigh your health, your other medicines and your coverage. In general:
Foundayo may fit you better if:
- an empty-stomach morning routine is hard for you, or your schedule changes from day to day;
- you take other pills in the morning, such as thyroid medicine;
- you want to take your pill with breakfast, coffee or later in the day.
The Wegovy pill may fit you better if:
- you want the larger average weight loss seen in its trial;
- you have heart disease, since only the Wegovy pill is approved to lower the risk of heart attack, stroke and heart-related death;
- you take birth control pills, or medicines that interact with Foundayo through CYP3A4;
- you're comfortable with a fixed morning routine.
Cost rarely decides it: self-pay prices are close, and both are in the Medicare GLP-1 Bridge.
Pill or Weekly Shot: Where Do Injections Fit?
If you're open to a weekly injection, Zepbound produced clearly more weight loss in its trial than either pill: 20.9% at 72 weeks on the 15 mg dose. The Wegovy 2.4 mg injection's 14.9% at 68 weeks was close to the Wegovy pill's result. These figures come from the labels and, again, from separate trials. Our guides to Wegovy pill vs injection and Foundayo vs Zepbound compare those choices. A pill doesn't avoid stomach side effects: nausea leads both labels, and nausea or other stomach upset is also what our members on weekly injections report most.
If you're paying cash, compounded injections cost less. Compounded semaglutide is prepared by a licensed pharmacy for one patient's prescription and is not FDA-approved, which means the FDA hasn't reviewed it for safety, effectiveness or quality. The same is true of compounded tirzepatide. Neither is Wegovy, Foundayo or Zepbound, and the trial results in this article have not been shown for them.
At MaxLife, compounded semaglutide is $89/mo flat and compounded tirzepatide is $120/mo flat: the same price at every dose, with no membership fee. The price includes the provider's review and follow-up, the medicine if prescribed, supplies and free expedited shipping. MaxLife is a telehealth patient management platform, not a pharmacy: an independent licensed provider decides whether a prescription is right for you.
Be clear about the trade. If your plan covers a brand pill and the savings card brings it to $25, or you qualify for the $50 Medicare Bridge, the brand will likely cost you less. If you have heart disease, ask your provider about the Wegovy pill's approved heart benefit. And MaxLife doesn't sell pills, so if a daily pill is what you want, ask a provider about Foundayo or the Wegovy pill.
How We Checked This Page
In November 2026, we re-read both labels on DailyMed, the FDA's November 9, 2026 safety notice, LillyDirect's and NovoCare's self-pay prices and the Medicare GLP-1 Bridge rules. Foundayo's reduced prices and its savings card end on December 31, 2026, so check LillyDirect for 2027 prices.
How we made this page: we researched it from the sources listed below and drafted it with the help of AI tools. The MaxLife operations team reviews every page before it goes live, and a licensed clinician also reviews our medical articles.
Frequently Asked Questions
Compounded Semaglutide $89/mo or Tirzepatide $120/mo
MaxLife compounded semaglutide $89 a month and tirzepatide $120 a month, flat. All-inclusive, no membership fee, the same price at every dose. A licensed provider decides.
Check Your EligibilityThis article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Individual results vary. Prices, coverage and compounding rules change; confirm current details with your prescriber, your plan or the seller before you decide.
Why trust our experts

April Foster, DO MPH
Reviewer
Board Certified Family Medicine Physician licensed nationwide providing collaborative oversight to NPs, PAs, and RN. Also specializing in telemedicine services nationwide.
Sources
- Foundayo (orforglipron) prescribing information (DailyMed)
- Wegovy (semaglutide) injection and tablets prescribing information (DailyMed)
- Zepbound (tirzepatide) prescribing information (DailyMed)
- FDA: FDA approves first new molecular entity under national priority voucher program (Foundayo), April 1, 2026
- Eli Lilly: FDA approves Foundayo (orforglipron), April 1, 2026
- Novo Nordisk: FDA approves Wegovy pill, December 22, 2025
- New England Journal of Medicine: Orforglipron, an oral small-molecule GLP-1 receptor agonist, for obesity (ATTAIN-1)
- New England Journal of Medicine: Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4)
- The Lancet: Once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3), 2026
- Eli Lilly: Foundayo ACHIEVE-2, ACHIEVE-3 and ACHIEVE-5 type 2 diabetes results, June 8, 2026
- Nature Medicine: Orforglipron for maintenance of body weight reduction (ATTAIN-MAINTAIN), 2026
- FDA Drug Safety Communication: safety labeling changes for GLP-1 receptor agonists due to potential risk of NAION, November 9, 2026
- LillyDirect: Foundayo self-pay pricing
- LillyDirect: Foundayo full terms and conditions
- NovoCare: Wegovy home delivery and self-pay pricing
- TrumpRx.gov: Foundayo (self-pay price and wholesale acquisition cost)
- TrumpRx.gov: Wegovy pill (self-pay price and wholesale acquisition cost)
- Novo Nordisk: Wegovy and Ozempic list price reduction effective January 1, 2027 (February 24, 2026)
- Medicare.gov: Weight loss drugs (Medicare GLP-1 Bridge)
- CMS: Medicare GLP-1 Bridge
- KFF: 2026 Employer Health Benefits Survey

Foundayo vs Zepbound: Pill or Weekly Shot?
November 14, 20269 min

Wegovy Pill vs Injection: Results, Side Effects and Cost Compared
November 5, 202611 min

GLP-1 Cost: What Every GLP-1 Costs Per Month, With and Without Insurance (2026)
November 17, 202610 min

Is There a Tirzepatide Pill? Foundayo and Oral Options
November 7, 20268 min
